

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/566,888	01/31/2006	Paul Goldsmith	6947-71693-01	9527
24197 7590 06/12/2008 KLARQUIST SPARKMAN, LLP 121 SW SALMON STREET			EXAMINER	
			BERTOGLIO, VALARIE E	
SUITE 1600 PORTLAND,	OR 97204		ART UNIT	PAPER NUMBER
,			1632	
			MAIL DATE	DELIVERY MODE
			06/12/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/566,888 GOLDSMITH ET AL. Office Action Summary Examiner Art Unit Valarie Bertoglio 1632 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on prel amdt 01/31/2006. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-5.7.8.10-13.18.21.22 and 41-46 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 1-5,7,8,10-13,18,21,22 and 41-46 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ______.

Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/566,888 Page 2

Art Unit: 1632

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-5,7,8,41 and 42, drawn to a screening method comprising administering an agent to a fish and determining the effect on the CNS.

Group II, claim(s) 10-13,18,21-22,43-46 drawn to a screening method comprising administering an agent to a fish and determining the effect on the CNS additionally comprising analysis of the agent to determine if it crosses the BBB.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

- A) The invention has no special technical feature that defined the contribution over the prior art,
- B) Unity of invention between different categories of inventions will only be found to exist if specific combinations of inventions are present. Those combinations include:
 - 1) A product and a special process of manufacture of said product.
 - 2) A product and a process of use of said product.
- 3) A product, a special process of manufacture of said product, and a process of use of said product.
 - 4) A process and an apparatus specially designed to carry out said process.
- 5) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

The allowed combinations do not include multiple products, multiple methods of using said products, and methods of making multiple products as claimed in the instant application, see MPEP § 1850.

Applicant's claims encompass multiple inventions and do not have a special technical feature which link the inventions one to the other, and lack unity of invention. The only technical feature linking the inventions is a method of screening a substance for activity in the CNS, which is not a contribution over the prior art (see Langheinrich, 2003, Bioessays, Vol.25, pages 904-912). There is no special technical feature common to each group because the special technical feature of each group resides in its own sequence.

This application contains claims directed to more than one species of the generic

invention. These species are deemed to lack unity of invention because they are not so linked as

to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

A) determining if the agent is transported by p-glycoprotein.

B) determining if interferes with p-glycoprotein function or alters p-glyocoprotein expression.

C) determining whether a combination of test substances have altered BBB penetration.

D) determining a body:brain drug concentration gradient.

E) determining relative efficacies of various test substances.

F) determining if the agent is transported by p-glycoprotein.

G) determining if the agent is metabolized by the BBB.

H) determining if the agent is actively transported across the BBB.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be

restricted if no generic claim is finally held to be allowable. The reply must also identify the claims

readable on the elected species, including any claims subsequently added. An argument that a claim is

allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to

additional species which are written in dependent form or otherwise include all the limitations of an

allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant

must indicate which are readable upon the elected species. MPEP § 809.02(a).

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species are drawn to analysis of various characteristics of a test substance. Langheinrich (above) taught pharmacological analysis of compounds after screening for desired in vivo activity

Application/Control Number: 10/566,888 Page 4

Art Unit: 1632

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named

inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of

inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37

CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Valarie Bertoglio whose telephone number is (571) 272-0725. The examiner can normally

be reached on Mon-Thurs 5:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter

Paras can be reached on (571) 272-4517. The fax phone number for the organization where this

application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained

from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer

Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR

CANADA) or 571-272-1000.

/Valarie Bertoglio/ Primary Examiner Art Unit 1632

... O.... 100=